Trial Search Results

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Concert Pharmaceuticals

Stanford Investigator(s):


  • Drug: CTP-543


Phase 2


Inclusion Criteria:

   - Have completed 24 weeks of treatment in a previous qualifying CTP-543 clinical trial

Exclusion Criteria:

   - Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical
   treatment to the scalp, significant trauma to the scalp, or untreated actinic

   - Females who are nursing, pregnant, or planning to become pregnant while in the study,
   and for 30 days after last dose of study medication

   - Donation of blood at any point throughout the study and for 30 days after last dose of
   study medication

Ages Eligible for Study

18 Years - 65 Years

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305